Core Viewpoint - 康龙化成 has announced a proposal to increase its registered capital and amend its articles of association, reflecting its ongoing growth and strategic initiatives [1] Group 1: Capital Increase - The company plans to increase its registered capital from RMB 1.778 billion (1.778 billion shares) to RMB 1.837 billion (1.837 billion shares) [1] - This increase is associated with the placement of a total of 58.4408 million new H-shares scheduled for January 22, 2026 [1] Group 2: Share Allocation - The proposal includes the allocation of a total of 647,300 restricted A-shares, which will be registered and listed for circulation on January 29, 2026, as part of the 2021 and 2022 A-share incentive plans [1]

智通财经APP讯，康龙化成(03759)发布公告，严洛钧先生已辞任本公司的公司秘书，及不再担任本公司 根据香港联合交易所有限公司证券上市规则第3.05条所规定的授权代表及香港法例第622章公司条例第 16部规定的本公司于香港接收法律程序文件及通知的代理人，自2026年3月30日生效。 麦宝文女士已获委任为公司秘书、授权代表及法律程序文件代理人，自2026年3月30日起生效。 ...

格隆汇3月30日丨康龙化成(300759.SZ)发布2025年年报显示，公司全年实现营业收入140.95亿元，同比 增长14.82%；归母净利润16.64亿元，同比下滑7.22%；扣非归母净利润15.38亿元，同比增长38.85%； 对全体股东10派2元。 ...

Core Viewpoint - Kanglong Chemical (300759.SZ) reported a revenue of 14.095 billion yuan for 2025, representing a year-on-year growth of 14.82%. However, the net profit attributable to shareholders decreased by 7.22% to 1.664 billion yuan, while the net profit excluding non-recurring items increased by 38.85% to 1.538 billion yuan. The company also proposed a cash dividend of 2 yuan per 10 shares (tax included) [1] Financial Performance - The company's total revenue reached 14.095 billion yuan, marking a 14.82% increase year-on-year [1] - Net profit attributable to shareholders was 1.664 billion yuan, reflecting a decrease of 7.22% [1] - Net profit excluding non-recurring items was 1.538 billion yuan, showing a significant increase of 38.85% [1] - Basic earnings per share stood at 0.9443 yuan [1] Strategic Initiatives - The company emphasizes a customer-centric service philosophy and leverages a fully integrated service platform to meet diverse global client needs [1] - There has been a notable performance in business with large pharmaceutical clients, indicating successful strategic client expansion [1] - The company is actively expanding its customer base and utilizing advanced technologies to empower new drug development, maintaining industry leadership in small molecules while rapidly developing new molecular types [1] - In the Chinese market, the company is implementing market strategies tailored to local conditions, resulting in rapid growth in business with Chinese clients [1] - The new order amount signed in 2025 increased by over 14% year-on-year [1]

Core Insights - The company reported a revenue of 14.095 billion yuan for the year 2025, representing a year-on-year growth of 14.82% [1] - The net profit attributable to shareholders decreased by 7.22% to 1.664 billion yuan, while the net profit excluding non-recurring items increased by 38.85% to 1.538 billion yuan [1] - The basic earnings per share were 0.9443 yuan, and the company proposed a cash dividend of 2 yuan per 10 shares (tax included) [1] Business Strategy - The company emphasizes a customer-centric service philosophy and leverages an integrated service platform to meet diverse global client needs across different research and development stages [1] - Significant achievements were noted in expanding strategic client relationships, particularly with large pharmaceutical companies [1] - The company is actively enhancing its market strategies tailored to the Chinese market, resulting in rapid growth in client business within China [1] Market Performance - The company achieved a more than 14% year-on-year increase in new order amounts for 2025 [1] - The company maintains industry leadership in small molecule fields while also experiencing rapid development in new molecular type projects [1]

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 Pharmaron Beijing Co., Ltd. （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 海外監管公告 本公告乃康龍化成（北京）新藥技術股份有限公司（「本公司」）根據香港聯合交易所 有限公司證券上市規則第13.10B條作出。 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 茲載列本公司於深圳證券交易所網站刊登公告如下，僅供參閱。 承董事會命 康龍化成（北京）新藥技術股份有限公司 主席 樓柏良博士 中華人民共和國，北京 2026年3月30日 於本公告日期，董事會包括執行董事樓柏良博士、樓小強先生及鄭北女士；職工 代表董事李承宗先生；非執行董事李家慶先生及萬璇女士；獨立非執行董事李麗 華女士、曾勁峰教授及余堅先生。 证券代码：300759 证券简称：康龙化成 公告编号：2026-010 康龙化成（北京） ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 截至2025年12月31日止年度全年業績公告 財務摘要及要點 截至12月31日止年度 | | 2025年 | 2024年 | 變動 | | --- | --- | --- | --- | | | 人民幣千元 | 人民幣千元 | % | | 收益 | 14,095,079 | 12,275,775 | 14.8 | | 毛利 | 4,857,334 | 4,149,255 | 17.1 | | 母公司擁有人應佔利潤 | 1,663,899 | 1,793,351 | (7.2) | | 母公司擁有人應佔非國際財務報告 | | | | | 準則經調整淨利潤 | 1,816,129 | 1,606,852 | 13.0 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不會就本公告全部或任何部份內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） (1)變更公司秘書、授權代表及法律程序文件代理人； (2)建議增加註冊資本；及 (3)建議修訂公司章程 康龍化成（北京）新藥技術股份有限公司（「本公司」）董事會（「董事會」）宣 佈，嚴洛鈞先生（「嚴先生」）已辭任本公司之公司秘書（「公司秘書」），及不再 擔任本公司根據香港聯合交易所有限公司（「聯交所」）證券上市規則第3.05條 所規定之授權代表（「授權代表」）及香港法例第622章公司條例第16部規定之 本公司於香港接收法律程序文件及通知之代理人（「法律程序文件代理人」）， 自2026年3月30日生效。 嚴先生確認彼與董事會並無任何意見分歧，亦無任何有關彼辭任之事項需要 提請聯交所及本公司股東（「股東」）注意。 嚴先 ...

EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 康龍化成（北京）新藥技術股份有限公司 | | | 股份代號 | 03759 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 截至2025年12月31日止年度之末期現金股息 | | | 公告日期 | 2026年3月30日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | 宣派股息的報告期末 | 2025年12月31日 | | 宣派股息 | 每 10 股 2 RMB | | 股東批准日期 | 有待公佈 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | HKD， 金額有待公佈 | | 匯率 | 有待公佈 | | ...

Revenue Performance - The company achieved operating revenue of 14.095 billion yuan in 2025, representing a year-on-year growth of 14.82%, maintaining double-digit growth for three consecutive years [1][16] - Revenue growth rates for different business segments were as follows: laboratory services at 15.78%, CMC (small molecule CDMO) services at 16.53%, and large molecule and cell and gene therapy services at 16.48%, all exceeding the overall growth rate. Clinical research services saw a slower growth rate of 7.14% [1][16] - By region, revenue growth was recorded at 10.97% in North America, 27.42% in Europe, and 15.69% in China, with Europe emerging as a new growth driver [1][16] Profitability Analysis - The net profit attributable to shareholders was 1.664 billion yuan in 2025, a decrease of 7.22% year-on-year, primarily due to a significant investment gain from the disposal of PROTEOLOGIX, INC. in the previous year and a substantial reduction in non-recurring gains this period [2][17] - Excluding non-recurring gains, the company achieved a net profit of 1.538 billion yuan, reflecting a significant year-on-year increase of 38.85%, indicating a notable improvement in core profitability [2][17] Earnings Per Share - Basic earnings per share slightly decreased to 0.9443 yuan, down 6.81% year-on-year, while the diluted earnings per share, excluding non-recurring items, increased significantly to 0.8439 yuan, up 38.85%, aligning with the growth in core net profit [4][19] Expense and R&D Investment - Total expenses for the company amounted to 2.775 billion yuan in 2025, a year-on-year increase of 12.68%, with an expense ratio of 19.69%, up 0.21 percentage points from the previous year [5][20] - R&D expenses grew significantly by 22.75% to 576 million yuan, indicating a strong commitment to technological innovation [5][20] - The number of R&D personnel reached 22,874, a year-on-year increase of 19.19%, with the proportion of personnel holding a master's degree or higher rising to 38.3% [7][23] Cash Flow Analysis - The net cash flow from operating activities was 3.221 billion yuan, reflecting a year-on-year growth of 25.01%, significantly outpacing revenue and net profit growth [9][24] - Investment cash outflows totaled 7.795 billion yuan, a year-on-year increase of 48.36%, with a net cash flow from investment activities of -4.374 billion yuan, indicating a substantial decline [10][25] - Financing cash inflows increased to 2.883 billion yuan, a year-on-year growth of 116.36%, with net cash flow from financing activities turning positive at 377 million yuan, alleviating funding pressure [11][26] Executive Compensation - The company's chairman, Dr. Boliang Lou, received a pre-tax compensation of 5.2174 million yuan, while other key executives received compensation ranging from 3.6 million to 4.4174 million yuan, indicating a reasonable incentive mechanism linked to company performance [13][28]